Aziende Chimiche Riunite Angelini Francesco A.c.r.a.f. S.p.a.

Euticals Spa

Prime European Therapeuticals S.p.a. in Forma Abbreviata Euticals S.p.a.

Barbara Garofalo

Guido Furlotti

Giorgina Mangano

Nicola Cazzolla

Maria Alessandra Alisi

Angelo Guglielmotti

Rosella Ombrato

Caterina Maugeri

Isabella Coletta

Patrizia Dragone

Beatrice Garrone

Alessandra Capezzone De Joannon

Tommaso Iacoangeli

Francesca Mancini

Gabriele Magaro'

Gabriele Magaro′

Gaia Corso

Mario Brufani

Lorenzo Polenzani

Adriana Caterina Maggi

Claudia Cavarischia

Luigi Filocamo

Luisa Maria Migneco

Rinaldo Marini Bettolo

Paolo Maria Farina

Gabriele Magaro

Gillian Ashcroft

Francesca Ceccacci

Roberta Joudioux

Adriana Maggi

The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.

Antibacterial compounds

The present invention relates to novel antibacterial compounds (1) as defined below, pharmaceutical compositions containing them and their use as antimicrobials. A compound of formula (1): A-L-Y-L-R&#x2014;B, wherein A is a cyclic group having one of the following formulae (I), (II) and (III), and wherein B is cyclic group having one of the following formulae (IV) to (IX). 

Antibacterial compounds having broad spectrum of activity

The present invention relates to novel benzoyl derivatives of 3-aminocarbazole, to a pharmaceutical composition containing them, to a method for preparing them and to the use of such compounds for the production of a drug that is useful in the treatment or prevention of disturbances associated with the production of prostaglandin E(PGE), for instance inflammatory processes, pain, fever, tumours, Alzheimer's disease and atherosclerosis.

3-aminocarbazole compound, pharmaceutical composition containing it and preparation method therefor

The present invention relates to the new use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3&#x3b2;) inhibitors and to their use in the treatment of GSK-3&#x3b2;-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.

Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors. The present invention relates to the 1H-indazole-3-carboxamide compounds for use as glycogen synthase kinase 3 beta (GSK-3&#x3b2;) inhibitors and to their use in the treatment of GSK-3&#x3b2;-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies. 

An (aza)indole derivative substituted in position 5, of formula (I) in which X, Y, Z, G1, G2, G3, R1, W, and R2 have the meanings given in the description, a pharmaceutical composition comprising it, and also intermediate compounds and a preparation process therefor. 

(Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor

The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to Formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.

1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40

The invention relates to 17&#x3b1;-(5-hydroxy-C-hydrocarbyl)-1,3,5(10)-estratrien-3,17&#x3b2;-diol derivatives having cicatrising activity, preferably for topical use on wounds, without significant systemic effects, and to pharmaceutical compositions containing them. In particular, the invention relates to estradiol 17&#x3b1;-(5-hydroxypentyn-1-yl)derivatives and 3-esters, 5'-esters and 3,5&#x2032;-diesters thereof and to a process for the preparation thereof by reaction of 3-OR-protected estrone with an alkali metal derivative of OR-protected 5-pentynol, followed by 3-, 5-&#x2032; or 3,5&#x2032;-esterif&#xca;cation.

17-alpha-substituted derivatives of estradiol with wound-healing activity

The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.

1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40

A 2-arylindole compound substituted in position 5, of formula (I): in which X, Y, Z, W, A, R and R' have the meanings given in the description, a pharmaceutical composition comprising it, and also intermediate compounds and a preparation process therefor. 

2-arylindole derivatives as nPGES-1 inhibitors

Growing community of inventors

Rome, Italy

Barbara Garofalo